Post Partum Hemorrhage Clinical Trial
Official title:
Bedside Assessment of Coagulation in Post-partum Hemorrhage by Thromboelastography (TEG ®6S)
Postpartum hemorrhage (PPH) is one of the leading causes of maternal deaths. Its prognosis is
directly influenced by the early diagnosis and treatment of the associated coagulopathy. In
this context, fibrinogen concentration is the best predictor of a severe PPH. The medical
interest of thromboelastography/elastometry to early detect and guide the rapid correction of
coagulopathy in PPH is regularly discussed.
The principal aim of this study is to evaluate the performance of a new hemostasis point of
care device (thromboelastography - TEG ®6S) for the diagnosis of coagulopathy during PPH.
A secondary aim will be to determine the normal values of TEG6S at the end of a normal
pregnancy.
Postpartum hemorrhage (PPH) is a complication of 5 to 10% of deliveries and is the leading
cause of maternal mortality, all over the world. In France, as in other developed countries,
20% of maternal mortality is related to PPH complications with a high rate of avoidance (85%)
due to inappropriate or delayed therapeutic measures). The management of PPH is based on
recommendations highlighting the need for early detection and treatment of coagulopathy,
which is predictive of the hemorrhage severity. The prognosis of the PPH is directly related
to the rapidity of the coagulopathy treatment (30 to 60 minutes after diagnosis). Severe PPH
is often associated with clotting disorders of either primary origin (disseminated
intravascular coagulation) or secondary origin (coagulation factors loss due to hemorrhage).
A hypofibrinogenemia < 2 g/L is the best predictor of a severe PPH with a positive predictive
value of 100% . Similarly, abnormal coagulation tests appear to be predictive of the severity
of the bleeding and the subsequent need for invasive procedures.
The assessment of coagulation is currently based on standard laboratory hemostasis tests, but
with delayed time to obtain results, generally greater than 60 minutes. Therefore, early and
fast assessment of hemostasis during PPH is essential to estimate the bleeding severity and
allow early and adequate administration of pro-coagulant products, leading to an improved
prognosis of PPH. The medical interest of thromboelastography (TEG) to early diagnose and
guide the treatment of a coagulopathy in PPH is regularly discussed.
A previous observational study performed by our team in 2013 during PPH (95 patients and133
samples) compared the TEG 5000 parameters with the standard laboratory hemostasis tests. Our
results confirm the good predictability of TEG 5000 for the early detection of a
hypofibrinogenemia ≤ 2 g / l and/or thrombocytopenia ≤ 80 000 platelets / mm3 (AUC between
0.91 and 0.97). Among the biological parameters analyzed by the TEG 5000, the parameters
K-MRTGG and FF-MRTGG (maximum rate of thrombus generation) were also evaluated. Their
predictabilities were as good as the usual K-MA or FF-MA (comparable AUC) and were available
more rapidly than usual parameters (3 ± 3 min for FF-MRTGG and 8 ± 3 min for K-MRTGG),
allowing a very early evaluation of hemostasis.
The aim of this prospective observational study is therefore to evaluate the performance of a
new delocalized hemostasis monitoring device (thromboelastography - TEG ®6S) for the
diagnosis of coagulopathy during PPH.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03680339 -
The Effect of Preoperative and Post Operative Misoprostol Administration on Intraoperative Blood Loss and Postpartum Hemorrhage in CS
|
Phase 4 | |
| Completed |
NCT03693599 -
Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean
|
Phase 4 | |
| Completed |
NCT03707132 -
Tourniquet Reduces Blood Loss in Postpartum Hemorrhage During Hysterectomy for Placenta Accreta
|
||
| Recruiting |
NCT02306733 -
Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally
|
Phase 3 | |
| Completed |
NCT01866241 -
Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage
|
Phase 3 | |
| Not yet recruiting |
NCT01236482 -
Oxytocin in Cesarean Delivery
|
Phase 4 | |
| Completed |
NCT03784794 -
Patient Blood Management for Massive Obstetric Hemorrhage
|
N/A | |
| Recruiting |
NCT04401839 -
Amr Maneuver for Prevention of Postpartum Hemorrhage
|
N/A | |
| Not yet recruiting |
NCT06219538 -
DAISY Uterine Drain Device Evaluation
|
N/A | |
| Completed |
NCT01863706 -
Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage
|
Phase 1 | |
| Not yet recruiting |
NCT05488457 -
Oxytocin Pharmacokinetics and Pharmacodynamics
|
Phase 2 | |
| Completed |
NCT04723979 -
NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL
|
||
| Terminated |
NCT04277962 -
Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial
|
N/A | |
| Completed |
NCT03570723 -
Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa
|
N/A | |
| Completed |
NCT03117647 -
Mansoura-VV Uterine Compression Suture for Primary Atonic Postpartum Hemorrhage
|
N/A | |
| Active, not recruiting |
NCT03069859 -
Use of TXA to Prevent Postpartum Hemorrhage
|
Phase 2 | |
| Not yet recruiting |
NCT03891082 -
A Comparative Study Between Bakri Balloon and B Lynch Suture Used to Control Primary Postpartum Hemorrhage After Cesarean Section
|
N/A | |
| Not yet recruiting |
NCT03463070 -
Misoprostol Before and After Cesarean Section
|
Phase 3 | |
| Recruiting |
NCT05532215 -
Sublingual Misoprostol in Reduction of Caesarean Blood Loss
|
N/A | |
| Not yet recruiting |
NCT06255496 -
QStat Cartridge in Obstetric Patients
|